TY - JOUR
T1 - Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database
AU - EUSTAR co-authors
AU - Maurer, Britta
AU - Graf, Nicole
AU - Michel, Beat A.
AU - Müller-Ladner, Ulf
AU - Czirják, László
AU - Denton, Christopher P.
AU - Tyndall, Alan
AU - Metzig, Carola
AU - Lanius, Vivian
AU - Khanna, Dinesh
AU - Distler, Oliver
AU - Tarner, Ingo H.
AU - Cerinic, Marco Matucci
AU - Guiducci, Serena
AU - Walker, Ulrich
AU - Lapadula, Giovanni
AU - Iannone, Florenzo
AU - Becvar, Radim
AU - Sierakowsky, Stanislaw
AU - Bielecka, Otylia Kowal
AU - Cutolo, Maurizio
AU - Sulli, Alberto
AU - Valentini, Gabriele
AU - Cuomo, Giovanna
AU - Vettori, Serena
AU - Riemekasten, Gabriele
AU - Rednic, Simona
AU - Nicoara, Ileana
AU - Kahan, André
AU - Allanore, Yannick
AU - Vlachoyiannopoulos, P.
AU - Montecucco, C.
AU - Caporali, Roberto
AU - Carreira, Patricia E.
AU - Novak, Srdan
AU - Varju, Cecilia
AU - Chizzolini, Carlo
AU - Kucharz, Eugene J.
AU - Kotulska, Anna
AU - Kopec-Medrek, Magdalena
AU - Widuchowska, Malgorzata
AU - Cozzi, Franco
AU - Rozman, Blaz
AU - Mallia, Carmel
AU - Coleiro, Bernard
AU - Gabrielli, Armando
AU - Farge, Dominique
AU - Hij, Adrian
AU - Airò, Paolo
AU - Hesselstrand, Roger
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2015
Y1 - 2015
N2 - Objectives To identify predictive parameters for the progression of skin fibrosis within 1 year in patients with diffuse cutaneous SSc (dcSSc). Methods An observational study using the EUSTAR database was performed. Inclusion criteria were dcSSc, American College of Rheumatology (ACR) criteria fulfilled, modified Rodnan skin score (MRSS) ≥7 at baseline visit, valid data for MRSS at 2nd visit, and available follow-up of 12±2 months. Worsening of skin fibrosis was defined as increase in MRSS >5 points and ≥25% from baseline to 2nd visit. In the univariate analysis, patients with progressive fibrosis were compared with non-progressors, and predictive markers with p<0.2 were included in the logistic regression analysis. The prediction models were then validated in a second cohort. Results A total of 637 dcSSc patients were eligible. Univariate analyses identified joint synovitis, short disease duration (≤15 months), short disease duration in females/patients without creatine kinase (CK) elevation, low baseline MRSS (≤22/51), and absence of oesophageal symptoms as potential predictors for progressive skin fibrosis. In the multivariate analysis, by employing combinations of the predictors, 17 models with varying prediction success were generated, allowing cohort enrichment from 9.7% progressive patients in the whole cohort to 44.4% in the optimised enrichment cohort. Using a second validation cohort of 188 dcSSc patients, short disease duration, low baseline MRSS and joint synovitis were confirmed as independent predictors of progressive skin fibrosis within 1 year resulting in a 4.5-fold increased prediction success rate. Conclusions Our study provides novel, evidence-based criteria for the enrichment of dcSSc cohorts with patients who experience worsening of skin fibrosis which allows improved clinical trial design.
AB - Objectives To identify predictive parameters for the progression of skin fibrosis within 1 year in patients with diffuse cutaneous SSc (dcSSc). Methods An observational study using the EUSTAR database was performed. Inclusion criteria were dcSSc, American College of Rheumatology (ACR) criteria fulfilled, modified Rodnan skin score (MRSS) ≥7 at baseline visit, valid data for MRSS at 2nd visit, and available follow-up of 12±2 months. Worsening of skin fibrosis was defined as increase in MRSS >5 points and ≥25% from baseline to 2nd visit. In the univariate analysis, patients with progressive fibrosis were compared with non-progressors, and predictive markers with p<0.2 were included in the logistic regression analysis. The prediction models were then validated in a second cohort. Results A total of 637 dcSSc patients were eligible. Univariate analyses identified joint synovitis, short disease duration (≤15 months), short disease duration in females/patients without creatine kinase (CK) elevation, low baseline MRSS (≤22/51), and absence of oesophageal symptoms as potential predictors for progressive skin fibrosis. In the multivariate analysis, by employing combinations of the predictors, 17 models with varying prediction success were generated, allowing cohort enrichment from 9.7% progressive patients in the whole cohort to 44.4% in the optimised enrichment cohort. Using a second validation cohort of 188 dcSSc patients, short disease duration, low baseline MRSS and joint synovitis were confirmed as independent predictors of progressive skin fibrosis within 1 year resulting in a 4.5-fold increased prediction success rate. Conclusions Our study provides novel, evidence-based criteria for the enrichment of dcSSc cohorts with patients who experience worsening of skin fibrosis which allows improved clinical trial design.
UR - http://www.scopus.com/inward/record.url?scp=84932632017&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2014-205226
DO - 10.1136/annrheumdis-2014-205226
M3 - Journal articles
C2 - 24981642
AN - SCOPUS:84932632017
SN - 0003-4967
VL - 74
SP - 1124
EP - 1131
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 6
ER -